Nanotechnology-Based Targeting of mTOR Signaling in Cancer
- Authors
- Yoon, M.-S.
- Issue Date
- Aug-2020
- Publisher
- DOVE MEDICAL PRESS LTD
- Keywords
- cancer; mammalian target of rapamycin; mTOR kinase inhibitor; nanoparticles; nanotechnology; RapaLinks; rapalogs
- Citation
- International journal of nanomedicine, v.15, pp.5767 - 5781
- Journal Title
- International journal of nanomedicine
- Volume
- 15
- Start Page
- 5767
- End Page
- 5781
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/78898
- DOI
- 10.2147/IJN.S254574
- ISSN
- 1176-9114
- Abstract
- Mammalian target of rapamycin (mTOR) is a master regulator of cell growth and metabolism, which is activated in response to intra- and extracellular signals, including nutrients, growth factors, and cellular energy levels. The frequent dysregulation of mTOR signaling in cancer makes it an attractive therapeutic target, and several types of mTOR inhibitors have been developed. Nanoparticle-based mTOR modulators are predicted to target various cancers and deliver as well as release drugs in a controlled manner, resulting in enhanced bioavailability and reduced side effects. This mini-review is focused on the molecular mechanism of nanoparticle-based mTOR modulator action as well as the current development of mTOR inhibitors using nanoparticles. Understanding the biological function of nanoparticle-based mTOR modulators will contribute to the development of efficient nano-therapeutics for the treatment of cancers. © 2020 Yoon.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의예과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/78898)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.